NASDAQ: ERASErasca Inc Stock
$1.88-0.05 (-2.59%)
Updated Apr 24, 2024
ERAS Price
$1.88
Fair Value Price
$0.25
Market Cap
$284.81M
52 Week Low
$1.51
52 Week High
$3.38
P/E
-2.27x
P/B
0.9x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$125.04M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.25
Operating Cash Flow
-$101M
Beta
1.42
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A
ERAS Overview
Erasca, Inc. is a clinical-stage biopharmaceutical company developing therapies for patients with RAS/MAPK pathway-driven cancers. Erasca's therapeutic strategies are (1) target key upstream and downstream signaling nodes in the RAS/MAPK pathway; (2) target RAS directly; and (3) target escape routes that emerge in response to treatment. The company's lead candidates include ERAS-007, ERAS-601, and ERAS-801. Erasca was incorporated in 2018 and is headquartered in San Diego, CA.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ERAS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ERAS ($1.88) is overvalued by 658.67% relative to our estimate of its Fair Value price of $0.25 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ERAS ($1.88) is not significantly undervalued (658.67%) relative to our estimate of its Fair Value price of $0.25 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ERAS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ERAS due diligence checks available for Premium users.
Be the first to know about important ERAS news, forecast changes, insider trades & much more!
ERAS News
Valuation
ERAS fair value
Fair Value of ERAS stock based on Discounted Cash Flow (DCF)
Price
$1.88
Fair Value
$0.25
Overvalued by
658.67%
ERAS ($1.88) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ERAS ($1.88) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ERAS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ERAS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.27x
Industry
15.69x
Market
41.27x
ERAS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.9x
Industry
5.86x
ERAS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ERAS's financial health
Profit margin
Revenue
$0.0
Net Income
-$29.7M
Profit Margin
0%
ERAS's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$395.3M
Liabilities
$78.6M
Debt to equity
0.25
ERAS's short-term assets ($320.68M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ERAS's short-term assets ($320.68M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ERAS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$24.8M
Investing
$4.5M
Financing
$456.0k
ERAS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ERAS vs Biotech Stocks
Erasca Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.